Ultragenyx Pharmaceutical Inc.

Historical 13F Holders

Symbol
RARE
CUSIP
90400D108
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 90400D108 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 8.3% 7/30/2026
Event 6/30/2026
RTW Investments, LP 13G
7.9% 8/14/2026
Event 6/30/2026
Vanguard Portfolio Management LLC 13G/A 7.0% 7/31/2026
Event 6/30/2026
AQR Capital Management, LLC 13G
6.7% 8/13/2026
Event 6/30/2026
State Street Corp 13G 6.3% 8/7/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.1% 7/31/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Sands Capital Management, LLC 13G/A
4.7% 2/12/2025
Event 12/31/2024
FMR LLC 13G/A
3.5% 2/5/2026
Event 12/31/2025
Wellington Management Group LLP 13G/A
2.7% 2/10/2025
Event 12/31/2024
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 4 3.65 k $54.8 k
2026 Q2 334 110 M $3.66 B
2026 Q1 317 98.2 M $2.06 B
2025 Q4 327 94.1 M $2.17 B
2025 Q3 339 99.5 M $2.99 B
2025 Q2 354 94.7 M $3.44 B
2025 Q1 331 89.9 M $3.26 B
2024 Q4 345 87.5 M $3.68 B
2024 Q3 328 87.3 M $4.84 B
2024 Q2 290 89.4 M $3.67 B
2024 Q1 292 81.2 M $3.79 B
2023 Q4 263 81.8 M $3.91 B
2023 Q3 242 71.3 M $2.54 B
2023 Q2 261 69.5 M $3.21 B
2023 Q1 245 69.2 M $2.77 B
2022 Q4 245 71.0 M $3.29 B
2022 Q3 256 68.3 M $2.83 B
2022 Q2 239 67.9 M $4.05 B
2022 Q1 259 67.8 M $4.91 B
2021 Q4 253 67.7 M $5.69 B
2021 Q3 231 66.7 M $6.01 B
2021 Q2 255 65.7 M $6.26 B
2021 Q1 277 67.9 M $7.73 B
2020 Q4 280 68.0 M $9.42 B
2020 Q3 218 63.2 M $5.20 B
2020 Q2 211 63.5 M $4.96 B
2020 Q1 190 60.8 M $2.70 B
2019 Q4 186 59.4 M $2.54 B
2019 Q3 183 59.1 M $2.53 B
2019 Q2 188 60.9 M $3.86 B
2019 Q1 190 58.4 M $4.05 B
2018 Q4 176 51.2 M $2.23 B
2018 Q3 193 50.6 M $3.87 B
2018 Q2 169 49.1 M $3.78 B
2018 Q1 174 49.3 M $2.51 B
2017 Q4 176 43.3 M $2.01 B
2017 Q3 167 40.6 M $2.17 B
2017 Q2 173 41.3 M $2.56 B
2017 Q1 178 40.8 M $2.76 B
2016 Q4 188 41.8 M $2.94 B
2016 Q3 193 39.7 M $2.82 B
2016 Q2 174 37.0 M $1.82 B
2016 Q1 172 37.4 M $2.37 B
2015 Q4 186 36.2 M $4.06 B
2015 Q3 177 35.7 M $3.49 B
2015 Q2 161 32.5 M $3.33 B
2015 Q1 132 31.6 M $1.96 B
2014 Q4 103 28.0 M $1.23 B
2014 Q3 107 26.5 M $1.50 B
2014 Q2 86 20.4 M $828 M
2014 Q1 78 18.9 M $815 M